The TOR inhibitors Rapamycin and AZD-8055 strongly reduce RPS6 phosphorylation and cell proliferation in Vasa2+/Piwi1+ cells. by Eudald Pascual-Carreras (12115380)

“…<i>n</i> = 2–4 biological replicates per condition, with 15 individuals per replicate. Significance levels for Student <i>t</i> test are indicated for adjusted <i>p</i> values: *<i>p</i> < 0.05, ***<i>p</i> < 0.001, ***<i>p</i> < 0.0001. d: day(s), n.s.: non-significant. …”

KO of iPLA₂γ attenuates development of albuminuria in STZ-induced diabetic nephropathy. by Andrey V. Cybulsky (4007012)

Subjects:

Control (Ctrl) STZ mice show changes in glomerular morphology. by Andrey V. Cybulsky (4007012)

Subjects:

Control (Ctrl) GECs are more susceptible to injury compared to iPLA₂γ KO GECs. by Andrey V. Cybulsky (4007012)

Subjects:

iPLA₂γ KO mice show increased glomerular autophagy. by Andrey V. Cybulsky (4007012)

Subjects:

Podocyte numbers in control and iPLA₂γ KO mice (WT1-positive cells). by Andrey V. Cybulsky (4007012)

Subjects:

STZ increases glomerular matrix expansion. by Andrey V. Cybulsky (4007012)

Subjects:

Primary data. by Andrey V. Cybulsky (4007012)

Subjects:

Receiver operating characteristic curve analyses for the prediction of hepatitis C. by Lu Han (151620)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Exploring the correlation between systemic inflammation biomarkers and HCV infection (logarithm base 2). by Lu Han (151620)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Threshold effect analysis of systemic inflammatory biomarkers on hepatitis C using two-piece wise linear regression. by Lu Han (151620)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Exclusion and enrollment summary from NHANES. by Lu Han (151620)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects: